CPP

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies

Retrieved on: 
måndag, juni 3, 2024
Adolphe, Splenic infarction, Prognosis, Deep vein thrombosis, SAE, Trial of the century, Pulmonary embolism, Percutaneous coronary intervention, MRS, Quality of life, University, EVT, Reperfusion, STEMI, Lancet Neurology, Safety, Northern General Hospital, Diabetes, Thrombectomy, Intracerebral hemorrhage, Infarction, CPP, PHRC, Death, FDA, ESOC, RHU, GREEN, Patient, NIHSS, Queen Elizabeth Hospital, Pathology, Stroke, SUSAR, Partnership, ANSM, Pharmaceutical industry

This reinforces our conviction that, despite the results presented at ESOC, glenzocimab still has a place in the treatment of cardiovascular emergencies in particular in the treatment of the acute phase of ischemic stroke.

Key Points: 
  • This reinforces our conviction that, despite the results presented at ESOC, glenzocimab still has a place in the treatment of cardiovascular emergencies in particular in the treatment of the acute phase of ischemic stroke.
  • The search for partners is now our priority to pursue product development, discussions have been initiated in this way."
  • This new clinical study is based on a long-standing collaboration between Acticor Biotech and the Hôpital Fondation Adolphe de Rothschild.
  • Acticor Biotech is also exploring other cardiovascular emergency indications for glenzocimab.

CPP Announces Acquisition of Corinthian House Affordable Development in San Jose, California

Retrieved on: 
tisdag, maj 21, 2024
Partnership, Community, CPP, Education, Silicon, Partner, Health, SAN, Common, WNC, Housing, Wi-Fi, Comerica, Good Samaritan Hospital, AMI, Acquisition, House, HAP, San Francisco Bay Area, Section 8, Quality of life, Citibank

SAN JOSE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- CPP (Community Preservation Partners), a mission-driven affordable housing preservation developer, has announced the acquisition and planned renovation of Corinthian House, a senior development in southwest San Jose, Calif.

Key Points: 
  • SAN JOSE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- CPP (Community Preservation Partners), a mission-driven affordable housing preservation developer, has announced the acquisition and planned renovation of Corinthian House, a senior development in southwest San Jose, Calif.
  • This is the fourth community in the Bay Area for CPP, joining Franco Center in Stockton, and El Rancho Verde and Lenzen Square Apartments in San Jose.
  • Built in 1982, Corinthian House is comprised of two elevator-served, three-story buildings on 1.75 acres.
  • “San Jose and nearby Silicon Valley have a desperate need for affordable housing, specifically for the underserved senior community,” said Karen Buckland, Vice President, Development at CPP.

Panbela Provides Business Update and Reports Q1 2024 Financial Results

Retrieved on: 
onsdag, maj 15, 2024
Doxorubicin, Patient, Doctor of Philosophy, Survival, Neuroblastoma, CPP, PBLA, AACR, Therapy, Overalls, Growth, Research, Topotecan, Note, Acquisition, Cyclophosphamide, Data analysis, Celecoxib, Loss, MSN, DFMO, OTCQB, Pharmaceutical industry

MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024.

Key Points: 
  • MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024.
  • Q1 2024 and recent Highlights:
    Announced revised timing for the interim data analysis for its ongoing ASPIRE trial, evaluating ivospemin (SBP-101) in combination with standard-of-care for metastatic pancreatic ductal adenocarcinoma (mPDAC).
  • On the financial and business front, we announced the transfer of our common stock to the OTCQB market and successfully closed a $9.0 million public offering.
  • Net proceeds from the raise, which closed on January 31, 2024, were approximately $8.1 million.

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Retrieved on: 
onsdag, maj 22, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Patient, HKEX, Pharmacokinetics, Infection, Toxicity, CPP, Disease, Skin, Safety, Psoriasis, VH, Autoimmunity, PASI, Pharmaceutical industry

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been dosed in a global Phase 2 clinical trial ( NCT06380907 ) evaluating the efficacy and safety of the company’s internally developed anti-IL-17 investigational therapy, ZL-1102, for the treatment of chronic plaque psoriasis (CPP).

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been dosed in a global Phase 2 clinical trial ( NCT06380907 ) evaluating the efficacy and safety of the company’s internally developed anti-IL-17 investigational therapy, ZL-1102, for the treatment of chronic plaque psoriasis (CPP).
  • Emphasizing its unique approach, ZL-1102 is being developed as a topical treatment for mild-to-moderate CPP, differentiating it from other anti-IL-17 products that target moderate-to-severe forms of the disease through systemic administration.
  • “ZL-1102 is the first IL-17 targeted topical treatment in development for patients with less severe forms of CPP.
  • In this 5-arm trial, approximately 250 patients will receive topical therapy for 16 weeks.

Update on the Brazilian Merger Review Process for the Sale of Terphane to Oben Group

Retrieved on: 
torsdag, maj 16, 2024
Other Manufacturing, Construction & Property, Steel, Packaging, Building Systems, Manufacturing, Machinery, Machine Tools, Metalworking & Metallurgy, Other Construction & Property, Residential Building & Real Estate, Tribunal, BOPP, CPP, BOPE, Sale, Aluminium, Administrative Council, BOPA, Tredegar Corporation, Oben

As previously announced, on September 1, 2023, Tredegar Corporation (NYSE: TG) entered into a definitive agreement to sell its flexible packaging films (“Terphane”) business to Oben Group.

Key Points: 
  • As previously announced, on September 1, 2023, Tredegar Corporation (NYSE: TG) entered into a definitive agreement to sell its flexible packaging films (“Terphane”) business to Oben Group.
  • Tredegar announced today that, as part of the Brazilian merger review process regarding the sale of Terphane to Oben Group, the General Superintendence of the Administrative Council for Economic Defense (“SG-CADE”) issued a non-binding opinion (“SG Opinion”) recommending the rejection of the transaction.
  • Following this first stage of the two-stage Brazilian merger review process for complex transactions, the case will now be submitted to the CADE Tribunal, in accordance with the customary Brazilian merger review process.
  • John Steitz, Tredegar’s president and chief executive officer, said, “We remain confident that the sale of Terphane to Oben Group will be a positive development for the flexible packaging films market in Brazil.

Imperial Dade Canada Adds Scale in Canada, Acquires Canpaco, Inc.

Retrieved on: 
onsdag, maj 15, 2024
Packaging, Retail, Manufacturing, Food, Beverage, CPP, Acquisition, Culture, Management

The transaction represents the 87th acquisition for Imperial Dade under the leadership of Robert and Jason Tillis, Chairman and CEO of Imperial Dade, respectively.

Key Points: 
  • The transaction represents the 87th acquisition for Imperial Dade under the leadership of Robert and Jason Tillis, Chairman and CEO of Imperial Dade, respectively.
  • Imperial Dade remains committed to the strategic focus created more than 15 years ago to continue to grow both through organic initiatives and a disciplined acquisition process.
  • "Imperial Dade continues to expand its presence across Canada, and we are looking forward to continuing together in our mission to organically grow and provide unmatched customer service throughout North America," said Jason Tillis, CEO of Imperial Dade.
  • "I enthusiastically welcome the Canpaco family to Imperial Dade Canada.

Prospective Study Shares Early Clinical Experience with Shape Memory Polymer Vascular Plugs for Pelvic Venous Disease

Retrieved on: 
måndag, maj 13, 2024
General Health, Surgery, Medical Devices, Infectious Diseases, Health, Patient, Doctor of Philosophy, Female, European Journal, CPP, Leal, Vascular surgery, Magnetic resonance, Blood, Pelvic pain, PVD, Gynaecology, Interventional radiology, University of Navarra, Chronic pain, Woman, Pain, Multimedia, Memory, Birth control

Shape Memory Medical Inc., developer of custom shape memory polymers for endovascular markets, announced the publication of a prospective observational study looking at the use of a single shape memory polymer plug, the IMPEDE-FX Embolization Plug, as the embolization agent to treat female pelvic venous disease (PVD).

Key Points: 
  • Shape Memory Medical Inc., developer of custom shape memory polymers for endovascular markets, announced the publication of a prospective observational study looking at the use of a single shape memory polymer plug, the IMPEDE-FX Embolization Plug, as the embolization agent to treat female pelvic venous disease (PVD).
  • In this prospective, observational case series, Jose Ignacio Leal Lorenzo, MD, PhD, and lead author, reports encouraging outcomes in this early experience.
  • Early Experience on Embolisation of Female Pelvic Venous Disease With a Single Shape Memory Vascular Plug: A Prospective Magnetic Resonance Imaging Based Evaluation, published by Leal et al, is available via open access at https://authors.elsevier.com/a/1iutJ3rFXltnme .
  • For more information about Shape Memory Polymer for Pelvic Venous Disorders, visit www.shapemem.com/pelvic-health .

New Markets: AITX's RAD Announces MOU to Collaborate with Commend Americas

Retrieved on: 
onsdag, maj 8, 2024
MOU, PSP, RAD, Safety, The Security Institute, CPP, Commendation ceremony, Communication, Partnership, Artificial intelligence, Growth, Mobile phone

The agreement establishes a framework for the collaboration between RAD and Commend to explore and potentially integrate their respective technologies and services.

Key Points: 
  • The agreement establishes a framework for the collaboration between RAD and Commend to explore and potentially integrate their respective technologies and services.
  • “This agreement marks the beginning of what we believe will be a highly fruitful partnership, presenting both parties with a wealth of exciting opportunities,” expressed Tom Reilly, President of Commend Americas.
  • “I was introduced to Commend 25 years ago when I was a low voltage integrator focused on the corrections market.
  • Commend had, and still holds, the esteemed position of simply being the best with audio and more,” commented Steve Reinharz, CEO/CTO of AITX and RAD.

Griffon Corporation Announces Second Quarter Results

Retrieved on: 
onsdag, maj 8, 2024
Commercial Building & Real Estate, Construction & Property, Other Retail, Building Systems, Specialty, Other Construction & Property, Retail, Residential Building & Real Estate, International, GFF, Corporation, CPP, Depreciation, MD, Griffon Corporation, Capital expenditure, Public expenditure, Tax, HBP, Griffon, Share repurchase, Calendar

Griffon Corporation (“Griffon” or the “Company”) (NYSE:GFF) today reported results for the fiscal 2024 second quarter ended March 31, 2024.

Key Points: 
  • Griffon Corporation (“Griffon” or the “Company”) (NYSE:GFF) today reported results for the fiscal 2024 second quarter ended March 31, 2024.
  • Revenue for the second quarter totaled $672.9 million, a 5% decrease compared to $711.0 million in the prior year quarter.
  • Adjusted EBITDA for the second quarter was $134.2 million, a 2% decrease from the prior year quarter of $136.9 million.
  • “Regarding capital allocation, during the fiscal second quarter, we repurchased more than 1.8 million shares at an average price of $65.09 per share.

ALE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ALLETE, Inc. Is Fair to Shareholders

Retrieved on: 
måndag, maj 6, 2024
Class Action Lawsuit, Professional Services, Legal, Sale, CPP, GIP, Global Infrastructure Partners, CPP Investment Board, Advertising, Fraud

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ALLETE, Inc. (NYSE: ALE) to Canada Pension Plan Investment Board (“CPP”) and Global Infrastructure Partners (“GIP”) for $67.00 per share in cash is fair to ALLETE shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ALLETE, Inc. (NYSE: ALE) to Canada Pension Plan Investment Board (“CPP”) and Global Infrastructure Partners (“GIP”) for $67.00 per share in cash is fair to ALLETE shareholders.
  • On behalf of ALLETE shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.